Harmony Biosciences (HRMY) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Harmony Biosciences Reports Second Quarter 2022 Financial Results and Business Updates
August 2, 2022 7:30 AM EDTWAKIX® (pitolisant) Net Revenue of $107.0 Million for Second Quarter 2022 Increase of 45% vs. the Same Period in 2021
Average Number of Patients on WAKIX Increased to ~4,300
Signs New Agreement with Bioprojet Focused on Developing Innovative Therapeutics Based on Pitolisant, Expanding Harmonys Opportunity in Narcolepsy
Phase 3 Idiopathic Hypersomnia (IH) INTUNE Study on Track with Site Activations and Patient Enrollment
Conference Call and Webcast to be Held Today at 8:30 a.m. ET
PLYMOUTH MEETING, Pa., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Harmony... More
